Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07313761 · ClinicalTrials.gov registry record · Phase 1

A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

A Phase 1 study of Overweight and Obesity, sponsored by Amgen.

Active
Registry status
Phase 1
Development phase
349
Enrollment target
4
Study locations

NCT07313761 is a Phase 1 study of Overweight and Obesity that is active but no longer recruiting, run by Amgen. The registered enrollment target is 349 participants, above the 225-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (55% higher). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07313761, a Phase 1 study of Overweight and Obesity, is active but no longer recruiting, sponsored by Amgen.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
349 participants
Enrollment target
4
Study locations

Study Summary

The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.

Conditions Studied

Overweight and Obesity

Interventions

  • DRUG Maridebart Cafraglutide

Study Locations (4)

California

  • Anaheim Clinical Trials - Anaheim
  • CenExel Collaborative Neuroscience Research, LLC Los Alamitos - Los Alamitos

Florida

  • Clinical Pharmacology Of Miami, LLC - Miami

Ohio

  • Ohio Clinical Trials, Inc. - Columbus

Trial Details

FieldValue
Enrollment Target 349 participants
Start Date 2025-12-15
Est. Completion 2026-06-26
Phase Phase 1

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07313761

The ClinicalTrials.gov registry entry for NCT07313761 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 349 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 225-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (55% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Overweight and Obesity appearing as the primary indexed condition, and to 1 intervention - of which Maridebart Cafraglutide is the first listed.

NCT07313761 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Ohio.

Frequently Asked Questions

What is clinical trial NCT07313761 about?

NCT07313761 is a clinical study titled "A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations". The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.

What is the current status of trial NCT07313761?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 349 participants. The study started on 2025-12-15. Estimated completion is 2026-06-26.

What conditions does trial NCT07313761 study?

This clinical trial studies the following conditions: Overweight and Obesity.

What interventions are being tested in trial NCT07313761?

The interventions under investigation include: Maridebart Cafraglutide (DRUG).

Who is sponsoring clinical trial NCT07313761?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07313761 being conducted?

This trial has 4 study locations across California, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Overweight and Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Overweight and Obesity

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.